As Bobe pointed out, two-thirds of them are engineers, many of them MIT-trained, and the other third are experts in drug development and commercialization.
In a May 10 interview, CEO Frank Bobe explained how the technology to enable this major boost in patient convenience and medical efficiency came from a technology developed by a pair of MIT materials scientists.